Introduction
Sialic acids (Sias) are typically attached to the outer end of cell surface and secreted glycoconjugates of higher animals (Schauer, 1982; Varki, 1992; Kelm and Schauer, 1997) . They can repel intermolecular and cell-cell interactions by virtue of their negative charge, as well as provide binding targets for viruses, bacteria, parasites, and toxins (Varki, 1997; Karlsson, 1998) . Their marked structural complexity with regard to internal modifications and linkages (Schauer, 1982; Varki, 1992; Ye et al., 1994; Kelm and Schauer, 1997 ) was thought to be related mostly to roles in host-pathogen interactions (Gagneux and Varki, 1999) . Indeed, a decade ago, the only example of a vertebrate Sia binding protein was factor H of the alternative complement pathway (Fearon, 1978; Pangburn and Muller-Eberhard, 1978) . It is now clear that Sias can be recognized by many specific lectins expressed by the same organism that synthesizes them (Varki, 1997) . Among these is a family of lectins called the Siglecs (Sialic acid-binding Ig-superfamily lectins) . The initially recognized members were Siglec-1(sialoadhesin, Sn, on macrophages), Siglec-2(CD22, on B cells), Siglec-3(CD33, on myelomonocytic cells), and Siglec-4a/4b (myelin-associated glycoprotein/ Schwann cell myelin protein, found on oligodendrocytes and Schwann cells in the nervous system) . Siglec-5 was subsequently discovered on neutrophils and monocytes (Cornish et al., 1998) and Siglec-6/OBBP-1 on B cells and placental trophoblasts (Patel et al., 1999) . Each Siglec preferentially recognizes aspects of its sialylated ligands, such as the side chain, the N-acyl group, the linkage from the 2-position, and sometimes the underlying sugars Sjoberg et al., 1994; Kelm et al., 1996; Shi et al., 1996; Collins et al., 1997a,b; May et al., 1998; Schnaar et al., 1998; Crocker et al., 1999; Sawada et al., 1999) . Siglec-6 also has a protein ligand, i.e., leptin (Patel et al., 1999) .
Assignment of specific functions to the Sia binding phenotype of the Siglecs is complicated, because these binding sites are often masked by endogenous ligands (Braesch-Andersen and Stamenkovic, 1994; Freeman et al., 1995; Hanasaki et al., 1995b; Sgroi et al., 1995; Sgroi et al., 1996; Collins et al., 1997b; Tropak and Roder, 1997) , and can be unmasked by sialidase treatment or cellular activation (Razi and Varki, 1998) . Recently, we reported that human blood leukocytes have Sia binding sites that can be unmasked by sialidase treatment (Razi and Varki, 1999) . Such unmasking occurred not only on B cells, monocytes and neutrophils (known to carry Siglecs) but also on natural killer cells and on a minority of mature T cells. The masking of such sites on unactivated cells may explain why many of these lectins have not been previously discovered. Here we report the discovery and characterization of a seventh member of the Siglec family. While this work was being prepared for submission, an apparent splice-variant of the same gene (p75/AIRM1) was independently reported by another group studying natural killer cells and also shown to bind erythrocytes in Sia-dependent manner (Falco et al., 1999) . We are also aware that yet another group has independently cloned the same gene product (P. Crocker, personal communication) .
Results

Identification of a cDNA clone homologous to Siglecs
The first 120 amino acid sequences of mouse Siglec-1 (GenBank accession #Z36293) and human Siglecs 2-6 (X59350, 4502654, M29273, 4502658, and 4502656, respectively) were used to carry out homology searches of the dbEST division of GenBank database. A human gall bladder cDNA (EST50650; GenBank accession #AA344713, The Institute for Genomic Research) was identified as a Siglec candidate, based on >50% homology to Siglecs 3, 5, and 6, and conservation of several amino acid residues common to previously known Siglecs (Cornish et al., 1998; Patel et al., 1999) . This clone was obtained via ATCC, and sequenced.
Cloning of a full-length cDNA encoding the putative Siglec-7
Since the clone lacked a coding sequence for the first half of an Ig-like domain, 5′-RACE and RT-PCR were performed, using human PBMC total mRNA as a template (PBMC were chosen based on preliminary Northern analysis using the partial clone). The full-length clone contained an open reading frame encoding 374 amino acids, starting with a typical signal sequence and two Ig-like domains, followed by a probable transmembrane domain and cytosolic tail (Figure 1 ). The cytosolic tail of the full-length protein contains two tyrosine residues, of which the first is contained in an Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM; S/I/L/VxYxxL/V). The second is in a motif [NEYSEI] similar, but not identical to the binding site on SLAM (Signaling Lymphocyte Activating Molecule) for SLAM-associated protein (SAP) (Sayos et al., 1998) . Nucleotide identity with other human Siglecs (first 750 nucleotides) are: Siglec-1, 45.9%; Siglec-2, 48.0%; Siglec-3, 63.6%; Siglec-4, 45.4%; Siglec-5, 64.0%; Siglec-6, 63.0%, and many of the residues typical of Siglecs are conserved (Figure 2a ). Siglec-7 formed a closely related cluster with Siglecs 3, 5, and 6 on an unrooted phylogram (Figure 2b ).
Sia-dependent erythrocyte-binding is abolished by conservative substitution of a single Arg residue
COS-7 cells were transfected with full-length Siglec-7 cDNA and interactions with human erythrocytes analyzed by a rosetting assay (Cornish et al., 1998) . Transfected COS cells bound human erythrocytes (Figure 3a) , and sialidase pretreatment of the erythrocytes completely abrogated the interaction ( Figure  3b ), indicating that Siglec-7 recognizes sialylated glycans on the erythrocyte surface. Binding occurred even when the COS cells were not pretreated with sialidase to remove potential cisligands that can engage some Siglecs. A specific Arg residue in Siglecs 1-4 is known to be required for Sia recognition, and is conserved among all Siglecs, including Siglec-7 (Figure 2a) . Introduction of conservative point-mutation (Arg124 to Lys) completely eliminated the binding of erythrocytes to transfected COS cells (Figure 3c,d ).
Recombinant Siglec-7 recognizes a specific sialyl linkage and requires the Sia side chain
A fusion protein of extracellular domains of Siglec-7 and human IgG Fc tail was produced and used in an ELISA assay. Among the ligands used, Neu5Acα2-6Galβ1-4Glc showed the best binding ( Figure 4 ). There was much weaker binding to probes carrying α2-3-linked Sias, including Neu5Acα2-3Galβ1-4Glc which differs only in the linkage of the Sia. Thus, Siglec-7 prefers α2-6-linked Sias. However, Neu5Acα2-6GalNAc also showed less binding, suggesting that the underlying glycan structure affects recognition. Sialidase treatment of the Neu5Acα2-6Galβ1-4Glc probe abolishes the binding of Siglec-7 ( Figure 5 ). Mild periodate treatment, which truncates the glycerol-like side chain of Sias and abolishes recognition by Siglecs 1-4 (Sjoberg et al., 1994; Shi et al., 1996; Collins et al., 1997b) also reduced recognition by Siglec-7 ( Figure 5 ), indicating that the Sia side chain is important for binding.
Tissue distribution of message expression
Northern blot analysis of normal human tissues ( Figure 6 ) indicates high expression in PBMC, spleen, and liver, and less prominent expression in lung and placenta. While the major mRNA species is estimated to be about 1.7 kb, there seem to be a shorter isoform (∼1.5 kb), notably in spleen. This result suggests that expression of isoforms may differ amongst tissues. The PBMC and splenic expression may be explained by the finding that NK cells carry this gene product (Falco et al., 1999) .
The Siglec-7 gene is on chromosome 19
The genes for human Siglecs 2-6 are known to be on chromosome 19, with Siglecs 3, 5, and 6 localized around 19q13.3-13.4 (Mucklow et al., 1995; Takei et al., 1997; Cornish et al., 1998) . From this fact and the high homology of Siglec-7 with the 3 Siglecs, we hypothesized a "Siglec gene cluster" around 19q13.3-13.4. Several BAC clones contiguously covering the chromosomal region containing the Siglec-3/CD33 gene were obtained, and screened for a clone containing Siglec-7 gene using PCR. Sequencing of PCR products revealed that a BAC clone which carries the Siglec-3/CD33 gene also contains the Siglec-7 gene. (a) Amino acid sequence alignment of the Siglec-7 with the most closely related Siglecs (3, 5, and 6) performed using Clustal W, with minimal manual adjustment. The * indicate identical residues, : indicates conservative differences. The conserved Arg residue that is mutated in this study is indicated with a box. (b) Phylogenetic analysis of the Siglec family using PAUP* 4.0 with results presented as an unrooted phylogram. Extent of divergence is indicated by the length of the lines between any two genes. Numbers near internodes indicate the Boot-strap values for 500 resamplings. Siglec-7 forms a clade with 3, 5, and 6 that appears to be distinct from the other three Siglec family members. A maximum likelihood-based reconstruction using Quartet Puzzling (Strimmer and von Haeseler, 1996) gave similar results.
Discussion
We have reported here a seventh member of the Siglec family, which shares the following features: a type 1 transmembrane topology with two or more Ig-like extracellular domains; an amino-terminal V-set Ig-like domain with characteristic sequence motifs and conserved cysteine residues; and specific recognition of Sia-containing glycans. Closer examination of the sequences indicates an ancestral relationship of the new gene with those of Siglecs 3, 5, and 6. In keeping with this, the four genes appear to be clustered around chromosome 19q13.3-13.4.
The Sia-binding properties of Siglec-7 are interesting. Among the potential targets studied, the preferred recognition motif is Neu5Acα2-6Galβ1-4Glc, which is very similar to the naturally occurring Siaα2-6Galβ1-4GlcNAc sequences of Nglycans in vertebrate systems. This motif is also recognized by Siglec-5 (Cornish et al., 1998) , and is the preferred ligand for Siglec-2 (Powell et al., 1993; Powell and Varki, 1994) . This may also explain why it was not necessary to treat Siglec-7 transfected COS cells with sialidase to unmask the binding site-COS cells have low endogenous levels of this structure. As with most other Siglecs, the actual binding affinity is likely to be low, and detection of specificity is achieved by the presentation of the cognate structures in multivalent arrays. While erythrocytes give robust Sia-dependent binding, this also represents an artificial situation. In the in vivo situation, erythrocytes are constantly bathed in plasma proteins that carry at least ∼1 mM concentration of glycosidically linked Siaα2-6Galβ1-4GlcNAc sequences (Hanasaki et al., 1995a) . Thus, the location and nature of the natural sialylated ligands of Siglec-7 remain to be determined.
Site-directed mutagenesis studies of Siglec-1 and Siglec-2 identified many residues in the amino-terminal V-set domain that were suggested to be involved in recognition of sialylated ligands Vinson et al., 1996) . However, the subsequently obtained crystal structure of Siglec-1 in complex with sialyllactose indicated that most of these effects had been due to a general disruption of protein folding (May et al., 1998) . However, one Arg residue (R97) that was originally mutated and led to loss of binding (Crocker et al., 1999) was in fact found to form a critical salt bridge with the carboxylate of the bound Sia (May et al., 1998) . Mutation of the corresponding Arg residue in Siglec-2 (Van der , Siglec-3 (Taylor et al., 1999) , and Siglec-4a (Tang et al., 1997) also resulted in loss of binding. This Arg residue is conserved among all the remaining Siglecs reported to date (see Figure 2a) . We therefore conservatively mutated this residue in Siglec-7 to a Lys residue, giving a complete loss of binding to erythrocytes, and to semi-synthetic ligands. Thus, one can predict that this Arg residue is critical to the binding of Sias by all Siglecs. This also allows us to suggest an in vivo approach to explore the function of the sialic binding properties of Siglecs. Partial or wholesale deletion of a Siglec molecule in the intact mouse is informative, but the results can be difficult to interpret, because more than just the sialic-acid binding property is eliminated. We suggest instead a "knockin" strategy, where the only change made would be the mutation of the critical Arg residue of a given Siglec into a Lys. This would leave the Siglec with all of its domains intact, but lacking only its Sia binding site. Such an experiment should be more informative with regard to the function of Sia recognition.
Regarding the biological significance of Sia recognition, the best studied example is Siglec-2. Genetic elimination in the intact mouse gives a phenotype of B cell dysregulation (O'Keefe et al., 1996; Otipoby et al., 1996; Sato et al., 1996; Cornall et al., 1998) . Genetic disruption of the ST6Gal I sialyltransferase that generates the CD22 ligand (Siaα2-6Galβ1-4GlcNAc) also gives suppression of B cell function, which is however more severe than that obtained by disruption of CD22 itself (Hennet et al., 1998) . This may now be explained by the fact that there are other Siglecs (3, 5, and 7) that can recognize the ST6Gal I product. The functions of Siglec-1 remain unclear, although it may be involved in macrophage interactions with developing myeloid cells (Crocker et al., 1990) and/ or cellular trafficking (Shi et al., 1996) . Regarding Siglec-4a, genetic disruption gives alterations in myelin sheath stability (Filbin, 1995) , which correlates with the Wallerian degeneration seen upon genetic elimination of its cognate ganglioside ligands (Sheikh et al., 1999) .
The biological functions of the CD33-related Siglecs (3, 5, 6, and 7) remain to be elucidated. There is a conserved consensus sequence surrounding the intracellular tyrosine residues of all four of these molecules [E(I/L)xYAxL-(12-18 residues)-(T/ N)EYSE(I/V)(K/R)] suggesting that they may associate with common intracellular signal transducers in their respective cell types. Indeed, as with Siglec-2 and 4a, the cytoplasmic tail of Siglec-3 is tyrosine-phosphorylated upon engagement (Taylor et al., 1999) . Once the tyrosines are phosphorylated, the first one is part of an ITIM (Immunoreceptor Tyrosine-based Inhibitory Motif; consensus: L/I/V/SxYxxL/V), which is found in many members of the Ig superfamily (including Siglec-2/ CD22), and forms a potential docking site for the SHP-1 tyrosine phosphatase. Of note, the second tyrosine-containing motif [(T/N)EYSE(I/V)] is similar to the sequence (TxYxxI/V) that has been reported in SLAM (Sayos et al., 1998) , an immunoregulatory molecule of the Ig superfamily. This motif is the docking site in SLAM for an SH2-containing molecule called SAP (SLAM-associated protein), which blocks recruitment of the tyrosine phosphatase SHP-2 to its docking site in the SLAM cytoplasmic region. We have postulated that a similar interplay occurs between the recruitment of phosphatases to the ITIM motif in Siglecs and the presence of SAP or SAP-like inhibitors to the SAP binding motif (Patel et al., 1999) .
Given the combination of an extracellular Sia binding site and an intracellular ITIM motif, it is reasonable to suggest that Siglec-7 is involved in transmembrane regulatory signaling of the types mentioned above. In this regard, a paper has just appeared reporting what appears to be the identical gene (the major cDNA reported has an additional extracellular C2-set Ig domain) (Falco et al., 1999) . These authors isolated this cDNA based on a monoclonal antibody directed against human natural killer cells, and showed that the protein negatively regulates the natural killer cell activity upon cross-linking by antibody. They also showed that the protein, when expressed on COS-7 cell, binds erythrocytes in Sia-dependent manner. While the relationship between Sia-binding at extracellular domain and signal transduction via intracellular domain of Siglec-7 is yet the be established, our recent finding that Sia binding sites on peripheral blood natural killer cells are masked by endogenous Sias (Razi and Varki, 1999 ) is of note in this context. Thus, if Siglec-7 indeed serves as an inhibitory receptor on natural killer cells, the Sias that regulate the signaling could be either on the same cell surface as the Siglec, or on another cell type. It also remains to be seen if Siglec-7 is expressed and functionally important on other cell types outside the hematopoietic system.
Materials and methods
5′-Rapid amplification of cDNA end (5′-RACE)
Total RNA from human peripheral blood mononuclear cells (PBMC) was obtained using an RNeasy Midi Kit (Qiagen). First strand cDNA was synthesized by reverse transcription (Superscript II, Life Technologies) of 0.5 µg of PBMC total RNA with a gene-specific primer SP1 (5′-GCCTTCTCCTTG-GAAGACAG-3′), and poly(dA) was added with dATP and terminal deoxynucleotidyl transferase. The cDNA was purified by QiaExII (Qiagen) and subjected to PCR. Gene-specific fragments were amplified by two rounds of nested PCR. In the first round, PS-NXB-dT (5′-GCTAGCTCGAGGATCCT 18 -3′) and SP2 (5′-ACAGTCAAGTTCTGAGGAGG-3′) were used as primers. The second round PCR used the first round PCR product as a template, and PS-NXB (5′-TTTGCTAGCTCGA-GGATCCT 4 -3′) and SP3 (5′-TCACGTTCACAGAGAGCT-GG-3′) as primers. The PCR product from the second round was directly sequenced.
Cloning and mutation of a full-length cDNA for Siglec-7
RT-PCR was performed using primers based on the DNA sequence of the EST clone and 5′ RACE product. First strand cDNA was synthesized by reverse transcription of 1 µg of PBMC total RNA with random DNA hexamers as primer. The reaction product was subjected to two rounds of PCR using Pwo DNA polymerase (Roche), using SLX-5′UTR (5′-CTCG-GATCCCTGGCACCTCTAACCC-3′) and SLX-3′UTR (5′-GGTCTAGAACCCTCAAACAAGCCC-3′) as primers. The PCR products were digested with BamHI and XbaI, ligated to BamHI-XbaI sites of pBluescript II KS(-) (Stratagene) and sequenced. A point mutation converting an Arg residue (R124) to Lys was introduced using QuickChange Site-Directed Mutagenesis Kit (Stratagene), following the manufacturer's protocol.
Northern blot analysis
A human 12-lane Multiple Tissue Nothern Blot (Clontech) was probed with the NcoI-XhoI fragment of the EST clone labeled with the Strip-EZ DNA kit (Ambion) and [α-32 P] 
dATP (NEN).
Hybridization signals were visualized using a Phosphor Imager.
Phylogenetic analysis of Siglecs
DNA sequences of human Siglecs 1-7 encoding the first two Ig-like domains (750 nt; the human Siglec-1 sequence was kindly provided by P.Crocker, Dundee, UK) were aligned by Clustal W at the European Bioinformatics Institute web site, and also subjected to phylogenetic analysis using PAUP* 4.0 (Sinauer Associates). The phylogenetic tree was constructed using the neighbor joining method (Saitou and Nei, 1987) . The distance matrix was based on Tamura-Nei genetic distances (Tamura and Nei, 1993) .
Expression of full-length Siglec-7 on COS-7 cells and erythrocyte rosetting
The full-length coding sequence of Siglec-7 (wild-type and R124K mutant) was amplified by PCR using the primers SLX 5′Chi (5′-CCTGTCGACGCCACCATGCTGCTGCTGCTG-CTGCTGCCC-3′) and SLX 3′UTR. The PCR fragment was treated with SalI and subcloned into the XhoI-EcoRV sites of pcDNA3.1(-) (Invitrogen), and sequenced. Constructs were transfected using LipofectAMINE reagent (Life Technologies) into COS-7 cells. After 48 h, cells were washed twice with PBS, treated with or without 10 mU Arthrobacter ureafaciens sialidase at 37°C for 1 h, and washed three times with rosetting assay solution (DMEM with 0.25% bovine serum albumin). Human erythrocytes (0.25% v/v; also pretreated with or without sialidase) in rosetting assay solution were layered on the COS-7 cells and incubated at 37°C for 30 min. Unbound erythrocytes were gently washed away, and rosettes observed under a microscope.
Production of recombinant chimeric proteins (Siglec-7-Fc)
A DNA fragment of Siglec-7 (wild-type and R124K) encoding the first two Ig-like domains was amplified by PCR using SLX 5′Chi and SLX 3′Chi (5′-CCTCATTTTGCCTGTGTACT-CCTG-3′) as primers. The fragment was cloned into the expression vector EK-Fc-pEdDC (prepared in this laboratory by Hui-ling Han), giving rise to a fusion protein of Siglec-7 extracellular domains and a human IgG Fc tail with a FLAG epitope tag (DYKDDDDK) in between. The constructs were transfected using LipofectAMINE into COS-7 cells or CHOTAg cells, culture supernatants collected, and the chimeric proteins purified on Protein A-Sepharose (Amersham Pharmacia Biotech).
Binding specificity of Siglec-7
Binding to sialylated oligosaccharides on polyacrylamide arrays (Glycotech) was performed as described (Patel et al., 1999) . Briefly, microtiter plate wells (Nunc, catalog #269620) were coated with protein A (0.5 µg/well) in 50 mM sodium carbonate-bicarbonate buffer, pH 9.5, at 4°C overnight, washed three times with ELISA buffer (20 mM HEPES, 1% bovine serum albumin, 125 mM NaCl, 1 mM EDTA, pH 7.45), blocked with ELISA buffer (RT, 1 h), and sequentially incubated at RT with the following (each incubation followed by 3 washes with ELISA buffer): Siglec-7-Fc (0.5 µg/well, human gamma globulin as negative control), 2 h; probes (1 µg/well), 2 h; streptavidin-conjugated alkaline phosphatase (1/1000 diluted from stock solution, Life Technologies), 1 h. After a final wash, p-Nitrophenyl Phosphate Liquid Substrate (Sigma) was added, incubated at RT for varying times (product formation was linear up to 18 h), and absorbance measured at 405 nm.
Mild periodate treatment of probes
The polyacrylamide probe carrying Neu5Acα2-6Galβ1-4Glc was subjected to mild periodate treatment, to truncate the glycerol-like side chain of Sia (Van Lenten and Ashwell, 1971) . Typically, 10 µg of the probe was incubated in 100 µl of 2 mM NaIO 4 in PBS for 30 min on ice in the dark. After the incubation, 100 µl of 20 mM NaBH 4 in PBS was added to the mixture and further incubated at RT for 1 h in the dark, to reduce aldehydes generated by periodate treatment. The mixture was diluted with 800 µl ELISA buffer and directly used in the assay.
Chromosomal localization of Siglec-7
From the physical map of human chromosome 19 (Human Genome Center, Laurence Livermore National Laboratory), BAC clones contiguously covering the region of chromosome 19 containing the Siglec-3/CD33 gene were identified and obtained through Research Genetics. The BACs were prepared by a modified alkaline lysis method (BACPAC Resources, Rosewell Park Cancer Institute), and subjected to PCR using SP1 and SP-5′ (5′-AAACTCGGGACCGATTCCAC-3′) as primers. PCR products were purified and directly sequenced.
